Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes

Blood (2019) 134 (Supplement_1): 506.

https://doi.org/10.1182/blood-2019-123974

Published: 2019

Journal Articles

Impact of a Tailored Nutritional and Physical Exercise Programme on Efficacy and Functional Outcomes in Older Patients with Hematological Malignancies Classified By Frailty Profile

Maite Antonio, MD PhD, Montserrat Arnan Sangerman, MD PhD, Eva Domingo-Domenech, MD, Eva González-Barca, MD PhD, Casimiro Javierre, MD PhD, Laura Hurtos, Judit Sola, Anna Sureda, MD PhD, Josep Maria Borras, MD PhD

Blood (2019) 134 (Supplement_1): 3424.

https://doi.org/10.1182/blood-2019-129908

Published: 2019

Journal Articles

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Franck Morschhauser, MD, Carmelo Carlo-Stella, MD, Fritz Offner, MD, Gilles A. Salles, MD PhD, Martin Hutchings, MD PhD, Gloria Iacoboni, MD, Anna Sureda, MD PhD, Michael Crump, MD, Joaquin Martinez-Lopez, MD PhD, Denise Thomas, MSc, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Ann-Marie E Bröske, PhD, Marina Bacac, PhD, Natalie Dimier, PhD, Tom Moore, MBChB, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 1584.

https://doi.org/10.1182/blood-2019-123949

Published: 2019

Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Giuseppe Gritti, MD PhD, Anna Sureda, MD PhD, Maria Jose Terol, Martin JS Dyer, DPhil, Gloria Iacoboni, MD, William Townsend, MRCP,MDFRCPath, Marina Bacac, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Angelika Lahr, PhD, Katharina Lechner, MD, Tom Moore, MBChB, Peter N Morcos, PharmD, Anesh Panchal, MSc, Martin Weisser, MD, Ciel De Vriendt

Blood (2019) 134 (Supplement_1): 2871.

https://doi.org/10.1182/blood-2019-123978

Published: 2019

Journal Articles

Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)?

Deepa Jagadeesh, MDMPH, Navneet S. Majhail, MD MS, He Yizeng, Kwang Woo Ahn, PhD, Carlos Litovich, MPH, Timothy S. Fenske, MD, Anna Sureda, MD PhD, Mohamed A Kharfan-Dabaja, MDMBA, Mehdi Hamadani, MD

Blood (2019) 134 (Supplement_1): 785.

https://doi.org/10.1182/blood-2019-121347

Published: 2019

Journal Articles

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Non-Hodgkin Lymphomas (NHL)-a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Nilanjan Ghosh, MD PhD, Sairah Ahmed, MD, Carlos Litovich, MPH, Kwang Woo Ahn, PhD, Manoj Khanal, Mohamed A Kharfan-Dabaja, MDMBA, Anna Sureda, MD PhD, Timothy S. Fenske, MD, Mehdi Hamadani, MD

Blood (2019) 134 (Supplement_1): 319.

https://doi.org/10.1182/blood-2019-121849

Published: 2019

Journal Articles

Subcutaneous Bortezomib, Thalidomide and Dexamethasone As Induction Therapy Prior to Autologous Peripheral Blood Stem Cell Transplantation in Young Patients Diagnosed of Multiple Myeloma. a Retrospective Analysis from Two Centers

David Jiménez Ruiz De La Torre, MD, Gladys Ibarra, MD, Maite Encuentra, Laura Abril, MD, Albert Oriol, MD, Josep-Maria Ribera, MD PhD, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 5568.

https://doi.org/10.1182/blood-2019-130107

Published: 2019

Journal Articles

Validation of Low Risk Prognostic Scoring System (LR-PSS) in Patients with Lower Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Montserrat Arnan Sangerman, MD PhD, Helena Pomares, MD PhD, Esther Alonso, MD, Mercedes Galiano, Maite Encuentra, Javier Grau, MD PhD, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 4270.

https://doi.org/10.1182/blood-2019-127901

Published: 2019

Journal Articles

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Montserrat Arnan Sangerman, Helena Pomares, MD PhD, Esther Alonso, MD, Javier Grau, MD PhD, Mercedes Galiano, Maite Encuentra, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 3013.

https://doi.org/10.1182/blood-2019-127486

Published: 2019

Journal Articles

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

Blood (2019) 134 (Supplement_1): 3152.

https://doi.org/10.1182/blood-2019-123560

Published: 2019

Journal Articles

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL):a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Sairah Ahmed, MD, Nilanjan Ghosh, MD PhD, Manoj Khanal, Kwang Woo Ahn, PhD, Carlos Litovich, MPH, Timothy S. Fenske, MD, Mohamed A Kharfan-Dabaja, MDMBA, Anna Sureda, MD PhD, Mehdi Hamadani, MD

Blood (2019) 134 (Supplement_1): 3318.

https://doi.org/10.1182/blood-2019-121848

Published: 2019

Journal Articles

Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial

Blood (2017) 130 (Supplement 1): 2017.

https://doi.org/10.1182/blood.V130.Suppl_1.2017.2017

Published: 2017

Journal Articles

Management and Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsed after Autologous Hemopoietic Stem Cell Transplantation (auto-HSCT): A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Blood (2017) 130 (Supplement 1): 2025.

https://doi.org/10.1182/blood.V130.Suppl_1.2025.2025

Published: 2017

Journal Articles

Treatment of Primary Cutaneous Marginal Zone B-Cell Lymphomas with Intralesional Rituximab

Eva Domingo Domenech, MD, Queralt Salas, MD, Octavio Servitje, MD PhD, Fina Climent, MD PhD, Helena Pomares, Ana Lucas, MD, Carmen Aguilera, Mrs, Alessandra Comai, Santiago Mercadal, MD, Eva Gonzalez Barca, PhD, Anna Sureda, MD PhD

Blood (2016) 128 (22): 1796.

https://doi.org/10.1182/blood.V128.22.1796.1796

Published: 2016

Journal Articles

Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Ramon Garcia-Sanz, MD PhD, Anna Sureda, MD PhD, Ana Pilar Gonzalez, MD, Fatima De la Cruz, MD PhD, Blanca Sanchez-Gonzalez, MD PhD, Antonia Rodriguez, MD PhD, Eva Domingo-Domenech, MD, Moreno Miriam, MD, Moreno Miriam, MD, Javier Lopez, Sr., MD PhD, Piñana Luis Jose, Gabriela Rodríguez, MD PhD, Miguel Canales, MD PhD, Antonio Gutierrez, MD PhD, Maria Dolores Caballero, MD PhD, Carmen Martinez, MD PhD

Blood (2016) 128 (22): 1109.

https://doi.org/10.1182/blood.V128.22.1109.1109

Published: 2016

Journal Articles

Improving Risk Stratification of Patients with Myelodysplastic Syndromes By the Integration of Red Blood Cell Transfusion Dependency into the Revised International Prognostic Scoring System

Montserrat Arnan, Helena Pomares, Isabel Sánchez-Ortega, MD PhD, Ester Alonso, MD, Maria Condom, Maite Encuentra, Javier Grau, Anna Sureda, MD PhD

Blood (2016) 128 (22): 3178.

https://doi.org/10.1182/blood.V128.22.3178.3178

Published: 2016

Journal Articles

Non-Cryopreserved Autologous Hematopoietic Transplantation Has Less Short Term Complications, Faster Engraftment and Similar Transplant Outcomes Than Cryopreserved Modality in Multiple Myeloma and Lymphoma Patients. a Comparative Analysis of Two Centers

Mauricio Sarmiento, MD, Rocio Parody, MD PhD, Queralt Salas, MD, Nicole Beffermann, MD, Veronica Jara, RN, Pablo A Bertin, MD, Isabel Sánchez-Ortega, MD PhD, Pablo Ramirez, MD, Mauricio Ocqueteau, MD, Beatriz Patiño, NG, Anna Sureda, MD PhD

Blood (2016) 128 (22): 2261.

https://doi.org/10.1182/blood.V128.22.2261.2261

Published: 2016

Journal Articles

Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT

Blood (2016) 128 (22): 678.

https://doi.org/10.1182/blood.V128.22.678.678

Published: 2016

Journal Articles

The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT)

Roni Shouval, MD, Joshua Fein, Myriam Labopin, Nicolaus Kroger, MD PhD, Rafael F. Duarte, MD PhD, Peter Bader, MD, Chiara Bonini, MD, Peter Dreger, MD, Carlo DuFour, MD, Andrew Gennery, MD, Jurgen Kuball, MD PhD, Francesco Lanza, MD, Silvia Montoto, MD, Emmanuelle Polge, John A Snowden, Jan Styczynski, MD PhD, Anna Sureda, MD PhD, Mohamad Mohty, MD PhD, Arnon Nagler

Blood (2016) 128 (22): 988.

https://doi.org/10.1182/blood.V128.22.988.988

Published: 2016

Journal Articles

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Shaji Kumar, MD, Meletios A Dimopoulos, Efstathios Kastritis, MD, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, MD, Jens Hillengass, MD, Xavier Leleu, Meral Beksac, MD, Melissa Alsina, MD, Albert Oriol, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Maria Victoria Mateos, Elizabeth K. O'Donnell, MD, Ravi Vij, MD MBA, Henk M. Lokhorst, MD PhD, Niels W.C.J. van de Donk, MD PhD, Chang-Ki Min, Tomer Mark, MD MSc, Ingemar Turesson, MD, PhD, Markus Hansson, MD, Heinz Ludwig, Sundar Jagannath, MD, Michel Delforge, MD PhD, Charalampia Kyriakou, MD PhD, Parameswaran Hari, MBBS, MD MRCP, Ulf-Henrik Mellqvist, MD PhD, Saad Z Usmani, MD FACP, Dominik Dytfeld, MD PhD, Ashraf Z Badros, MD, Philippe Moreau, Kihyun Kim, MD PhD, Paula Rodriguez Otero, MD, Jae Hoon Lee, MD, Chaim Shustik, MD, Daniel Waller, PhD, Wee Joo Chng, MD PhD, Shuji Ozaki, MD PhD, Je-Jung Lee, Javier de la Rubia, Hyeon Seok Eom, MD PhD, Laura Rosinol, MD PhD, Juan José Lahuerta, MD PhD, Anna Sureda, MD PhD, Jin Seok Kim, MD PhD, Brian G.M. Durie, MD

Blood (2016) 128 (22): 4414.

https://doi.org/10.1182/blood.V128.22.4414.4414

Published: 2016

NARROW

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes

Impact of a Tailored Nutritional and Physical Exercise Programme on Efficacy and Functional Outcomes in Older Patients with Hematological Malignancies Classified By Frailty Profile

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)?

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Non-Hodgkin Lymphomas (NHL)-a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Subcutaneous Bortezomib, Thalidomide and Dexamethasone As Induction Therapy Prior to Autologous Peripheral Blood Stem Cell Transplantation in Young Patients Diagnosed of Multiple Myeloma. a Retrospective Analysis from Two Centers

Validation of Low Risk Prognostic Scoring System (LR-PSS) in Patients with Lower Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL):a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial

Management and Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsed after Autologous Hemopoietic Stem Cell Transplantation (auto-HSCT): A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Treatment of Primary Cutaneous Marginal Zone B-Cell Lymphomas with Intralesional Rituximab

Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Improving Risk Stratification of Patients with Myelodysplastic Syndromes By the Integration of Red Blood Cell Transfusion Dependency into the Revised International Prognostic Scoring System

Non-Cryopreserved Autologous Hematopoietic Transplantation Has Less Short Term Complications, Faster Engraftment and Similar Transplant Outcomes Than Cryopreserved Modality in Multiple Myeloma and Lymphoma Patients. a Comparative Analysis of Two Centers

Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT

The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT)

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only